AOL Money & Finance

Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...

More

Analyst upgrades:

  • Deutsche Bank upgraded Vale SA (NYSE: VALE) to Buy from Hold on expectations the company will benefit from higher realized prices. The firm raised its target on shares to $30 from $23.
  • Soleil upgraded Education Management (NASDAQ: EDMC) to Buy from Gradually Accumulate following the company's Q1 results and raised its target on shares to $34 from $32.
  • Credit Suisse upgraded Medtronic (NYSE: MDT) to Outperform from Neutral. The firm also added the stock to its Focus List and raised its target on shares to $49 from $41. Credit Suisse believes Medtronic's base business is stabilizing and the stock's risk/reward is compelling.
  • Medivation (NASDAQ: MDVN) was upgraded to Buy from Hold at Roth Capital.
  • Martha Stewart (NYSE: MSO) was upgraded to Buy from Hold at Morgan Joseph.
  • Dominion Resources (NYSE: D) was upgraded to Hold from Underperform at Jefferies.

Analyst downgrades:

  • Collins Stewart downgraded Comcast (NASDAQ: CMCSA) to Hold from Buy to reflect overhang from the NBCU deal and lower-than-expected medium-term growth prospects.
  • RBC Capital downgraded Garmin (NASDAQ: GRMN) to Underperform from Sector Perform on concerns of increased competition and execution risk. The firm lowered its target on shares to $24 from $28.
  • Stephens downgraded Alvarion (NASDAQ: ALVR) to Equal Weight from Overweight on a lack of near-term catalysts and contract uncertainty. The firm lowered its target on shares to $5 from $7.
  • Approach Resources (NASDAQ: AREX) was downgraded to Neutral from Overweight at JPMorgan.
  • THQ Inc. (NASDAQ: THQI) was downgraded to Hold from Buy at Deutsche Bank.
  • Molson Coors (NYSE: TAP) was downgraded to Neutral from Buy at Goldman.

Analyst initiations:

  • Merriman initiated Novavax (NASDAQ: NVAX) with a Buy rating. The firm believes Novavax has a top technology in vaccine development for infectious diseases and set a $6-$8 price target on shares.
  • Merriman also started YM Biosciences (AMEX: YMI) with a Buy rating. The firm expects Nimotuzumab news flow to drive YM Biosciences shares.
  • Shanda Games (NASDAQ: GAME) was initiated with an Outperform rating and $16 target at Oppenheimer.
  • Fortune Brands (NYSE: FO) was initiated with a Neutral rating at BofA/Merrill.
  • Eaton (NYSE: ETN) was initiated with a Neutral rating and $70 target at Baird.

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br /> tags.

Symbol Lookup
IndexesChangePrice
DJIA+132.7910,450.95
NASDAQ+29.972,176.01
S&P 500+14.861,106.24

Last updated: November 24, 2009: 05:33 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

    BioHealth Investor Headlines

    WalletPop Headlines

    My Portfolios

    Track your stocks here!

    Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

    BloggingStocks Partners

    More from AOL Money & Finance

    WalletPop Headlines